elhamkhani
/
Test2
/
Login
Register
TriplyDB
Test2
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q38630472-52763C0B-463D-4822-8EB8-45AAB5ED1AE2
Q38630472-52763C0B-463D-4822-8EB8-45AAB5ED1AE2
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38630472-52763C0B-463D-4822-8EB8-45AAB5ED1AE2
Advances in targeted therapy for the treatment of patients with relapsed/refractory multiple myeloma.
P2860
Q38630472-52763C0B-463D-4822-8EB8-45AAB5ED1AE2
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38630472-52763C0B-463D-4822-8EB8-45AAB5ED1AE2
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
514e09bcf9836d3f35299cec35375b9cb7902d30
P2860
An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma.